SOURCE: Basilea Pharmaceutica AG

September 13, 2007 13:27 ET

New Data to be Presented on Key Basilea Compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

BASEL, SWITZERLAND--(Marketwire - September 13, 2007) - New data on Basilea's late-stage clinical compounds ceftobiprole and isavuconazole, as well as on its research programs, will be presented at the upcoming ICAAC meeting to be held in Chicago on September 17-19. The extensive new data reflects Basilea's ongoing efforts in the development of innovative antibacterials and antifungals addressing areas of high unmet medical need.

A series of 23 posters and one presentation will discuss clinical, microbiological and epidemiological data related to ceftobiprole, an investigational broad-spectrum cephalosporin antibiotic with anti-MRSA (methicilin-resistent Staphylococcus aureus) activity developed in collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., in pre-registration stage. Additionally, two posters present preclinical and clinical data on isavuconazole, an antifungal of the azole class currently in phase III clinical trials for the treatment of severe invasive fungal infections.

Ceftobiprole Clinical Data

Ceftobiprole (BPR) as Treatment of Complicated Skin and Skin Structure Infections (cSSSI) Caused by Panton-Valentine Leukocidin (PVL)-Positive Staphylococci. R. S. Strauss and co-authors. Poster K-1092 Microbiological Eradication of Gram-positive and Gram-negative Bacteria with Ceftobiprole (BPR) in Complicated Skin and Skin Structure Infections (cSSSI). R. S. Strauss and co-authors. Poster L-1143 Successful Treatment of Complicated Skin and Skin Structure Infections (cSSSI) Due to a Broad Spectrum of Bacteria with Ceftobiprole (BPR). R. S. Strauss and co-authors. Poster L-1145 Molecular Characterization of Methicillin-Resistant Staphylococcus aureus from Two Ceftobiprole Phase 3 Clinical Trials. T. A. Davies and co-authors. Poster C2-185 Ceftobiprole Activity against Pathogens from Two Complicated Skin and Skin Structure Infection (cSSSI) Clinical Trials. K.M. Amsler and co-authors. Poster E-282 Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with cSSSI. H. Kimko and co-authors. Slide Presentation A-590

Ceftobiprole Epidemiological and Microbiological Data

See Posters: A-38, E-277, E-272, E-275, E-276, E-278, C2-867, E- 274, C2-138, C1-93, C1-104,D-233, A-36, A-37, E-273, C1-844, C1-843, A-1438

Isavuconazole Pre-clinical and Clinical Data

Effect of Isavuconazole on the Pharmacokinetics and the Pharmacodynamics of S- and R-Warfarin A. Schmitt-Hofmann and co-authors. Poster A-776 Efficacy of Isavuconazole, Voriconazole and Fluconazole in a Neutropenic Murine Model of Candida krusei. J. Majithiya and co-authors. Poster M-1838

Another series of eight posters will outline in vitro profiles of Basilea's early stage compounds targeting resistant Gram-negative pathogens, specifically the activity of the new antibiotic BAL30376 is highlighted. Additionally, four posters will present data on a series of novel antifolate antibiotics with potential for oral treatment of resistant Gram-positive infections such as those caused by methicillin-resistant staphylococci. First clinical data on the macrolide antibiotic BAL19403 will also be presented.

In vitro Data of BAL30376 and Related Compounds

Activity of Monobactam/beta-Lactamase Inhibitor Combinations Against beta-Lactam-Resistant Gram-negative Bacteria. M.G.P. Page and co-authors. Poster F1-311 Activity of BAL30376 Against Gram-negative Bacteria. M.G.P. Page and co-authors. Poster F1-312 In vitro Potency of BAL30376 Against Gram-negative Bacilli (GNB). K. Bowker and co-authors. Poster F1-313 A Monobactam Plus Double beta-Lactamase Inhibitor Combination Designed to Overcome Multiple Resistance in Gram-negative Bacilli: Proof of Concept in an in vitro Pharmacokinetic Model. K. Bowker and co-authors. Poster F1-314 Efficacy of BAL30376 in a Murine Model of Gram-negative Sepsis. A. Schmitt-Hoffmann and co-authors. Poster F1-315 Activity of BAL30376 Against Multidrug Resistant (MDR) Klebsiella and Acinetobacter sp. G. Hujer and co-authors. Poster F1-333a Antimicrobial Activity of Novel Monobactams. E. Desarbre and co-authors. Poster F1-351 Novel Mono- and Bicyclic Monobactams as Potent Inhibitors of Class C beta-Lactamases. B. Gaucher and co-authors. Poster F1-310

In vitro Data of Antifolates

See Posters: F1-932, F1-933, F1-934, F1-935

First Clinical Data on Macrolide BAL19403


For abstracts of all posters please log on to

About Basilea

Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX: BSLN). Basilea is currently focused on the research, development and commercialization of new antibacterial, antifungal and dermatology drugs.


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

| General Information     | Investor Relations             |
| | Dr. Barbara Zink               |
|                         | |

This press release can be downloaded from

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information